Comparative Pharmacology
Head-to-head clinical analysis: ANTIZOL versus PRALIDOXIME CHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANTIZOL versus PRALIDOXIME CHLORIDE.
ANTIZOL vs PRALIDOXIME CHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antizol (fomepizole) is a competitive inhibitor of alcohol dehydrogenase, the enzyme that catalyzes the oxidation of ethanol to acetaldehyde. It also inhibits the metabolism of ethylene glycol and methanol to their toxic metabolites.
Pralidoxime chloride is a cholinesterase reactivator. It reactivates acetylcholinesterase that has been inactivated by phosphorylation due to organophosphate or carbamate exposure by binding to the organophosphate moiety and cleaving the enzyme-phosphate bond, thereby restoring enzymatic activity. It also has direct antimuscarinic and antinicotinic effects at high doses.
Initial: 15 mg/kg IV over 10 minutes, then 3 mg/kg IV every 4 hours for 2 doses, then 3 mg/kg IV every 6 hours for 4 doses.
1-2 g IV over 15-30 minutes, may repeat in 1 hour if muscle weakness persists, then every 10-12 hours as needed; typically given with atropine. Maximum dose: 2 g/hour or 12 g/day.
None Documented
None Documented
Terminal elimination half-life: 2.5-3.5 hours in adults. Clinical context: Dose adjustment recommended in severe renal impairment (CrCl <30 mL/min) due to prolonged half-life.
Terminal elimination half-life is approximately 1.5–2.5 hours in adults. In renal impairment, half-life may be prolonged up to 5–6 hours, necessitating dose adjustment.
Renal: 80-95% as parent drug and metabolites. Fecal: <5%. Biliary excretion is negligible.
Renal: >90% as unchanged drug and metabolites (including pyridone and pyridinium derivatives). Biliary/fecal: <5%.
Category C
Category C
Antidote
Antidote